Loading...
01/11 08:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong revenue growth and improved gross margins, suggesting positive financial performance. Despite increased operating expenses and net losses, the company maintains a solid cash position post-IPO. The Q&A indicates strategic investments in sales infrastructure and R&D, with a focus on future growth. While there are concerns about supply chain tariffs and unclear FDA submission details, the overall sentiment is optimistic, with expectations of accelerated growth post-2025. Given these factors, the stock is likely to experience a positive movement in the near term.
Q4 2024 Revenue $18.5 million, reflecting a 41% increase from $13.1 million in Q4 2023, driven by continued commercial expansion and increased adoption of the CeriBell System.
Full-Year 2024 Revenue $65.4 million, representing a 45% growth over 2023, attributed to strong performance in acquiring and launching new accounts and driving utilization.
Q4 2024 Product Revenue $14.1 million, a 41% increase from $10.0 million in Q4 2023, driven by commercial expansion.
Q4 2024 Subscription Revenue $4.4 million, a 40% increase from $3.1 million in Q4 2023, reflecting growth in active accounts.
Q4 2024 Gross Margin 88%, compared to 85% in Q4 2023, due to improved manufacturing efficiency and volume-based leverage.
Full-Year 2024 Gross Margin 87%, compared to 84% in 2023, reflecting continued efficiency improvements.
Q4 2024 Operating Expenses $29.1 million, a 49% increase from $19.5 million in Q4 2023, primarily due to investments in the commercial organization and increased headcount.
Full-Year 2024 Operating Expenses $96.5 million, an increase of 41% compared to $68.2 million in 2023, driven by investments in commercial growth and public company transition costs.
Q4 2024 Net Loss $12.6 million, or a loss of $0.40 per share, compared to a loss of $8.3 million or $1.53 per share in Q4 2023, reflecting increased operating expenses.
Full-Year 2024 Net Loss $40.5 million, or a loss of $3.39 per share, compared to a loss of $29.5 million or $5.56 per share in 2023, due to higher operating expenses.
Cash and Cash Equivalents $194.4 million as of December 31, 2024, including net proceeds of approximately $188 million from the October IPO.
Product Revenue Q4 2024: Product revenue for the fourth quarter of 2024 was $14.1 million, representing an increase of 41% from $10.0 million in the fourth quarter of 2023.
Subscription Revenue Q4 2024: Subscription revenue for the fourth quarter of 2024 was $4.4 million, representing an increase of 40% from $3.1 million in the fourth quarter of 2023.
New Product Indications: We expect to have Clarity indication expanded to include pediatric patients following our submission of a 510(k) application with FDA in late 2024.
Stroke Detection Algorithm Development: We have recently accelerated our investment in the development of a stroke detection algorithm, having collected data on over 200 patients.
Active Accounts: Our active account set at 529 accounts as of December 31, an increase of 25 during the first quarter.
Market Expansion Strategy: We intend to continue targeting the approximately 5,500 remaining prospective accounts through the efforts of our growing and increasingly tenured team of territory managers.
Total Addressable Market (TAM): We remain focused on achieving our previously communicated goal to reach 55 territory managers by the end of Q2.
Gross Margin Q4 2024: Gross margin for the fourth quarter of 2024 was 88% compared to 85% in the prior year period.
Operating Expenses Q4 2024: Total operating expenses for the fourth quarter of 2024 were $29.1 million, an increase of 49% compared to $19.5 million in the fourth quarter of 2023.
Strategic Focus for 2025: Our commercial strategy for 2025 is to maintain our key areas of focus and build upon our success in 2024.
Investment in R&D: We expect to accelerate hiring plans for key R&D talent and make greater investments across our pipeline to facilitate TAM expansion.
Regulatory Issues: CeriBell is preparing to submit a 510(k) application with the FDA for expanding the Clarity indication to include pediatric patients, which involves regulatory risks and uncertainties.
Supply Chain Challenges: The company faces a 35% tariff on materials sourced from China, which has increased from 25% in 2024, potentially impacting costs and supply chain stability.
Competitive Pressures: CeriBell operates in a competitive market with approximately 6,000 acute care facilities in the U.S. that could benefit from their offerings, indicating a need for continuous innovation and market penetration.
Economic Factors: The transition to operating as a public company has increased costs, particularly in stock-based compensation, which is expected to contribute approximately $15 million to operating expenses for the full-year 2025.
Operational Risks: The company anticipates that accelerated initiatives in R&D and commercial infrastructure may not drive revenue in the near term, posing a risk to short-term financial performance.
Commercial Strategy for 2025: Maintain key areas of focus and build upon success in 2024, expand account acquisition team to 55 territory managers by mid-2025.
R&D Pipeline Expansion: Invest in optimizing algorithm performance and user experience, expand indications beyond seizure management.
New Product Development: Focus on developing algorithms for delirium detection and stroke detection, with FDA submissions planned.
Market Expansion: Target the remaining 5,500 acute care facilities in the U.S. to drive adoption of CeriBell System.
2025 Revenue Guidance: Expected total revenue in the range of $81 million to $85 million, representing 24% to 30% growth over 2024.
Gross Margin Outlook: Expected to normalize and remain in the mid to high 80% range.
Operating Expenses: Stock-based compensation expected to contribute approximately $15 million to operating expenses for 2025.
Hiring Plans: Accelerate hiring for key R&D talent to pursue multiple opportunities in parallel.
Shareholder Return Plan: CeriBell plans to utilize proceeds from its IPO to strategically invest in initiatives designed for long-term growth, including hiring key R&D talent and expanding its pipeline. The company aims to achieve cash flow breakeven with the cash on hand from the IPO.
Stock-Based Compensation: Stock-based compensation is expected to contribute approximately $15 million to operating expenses for the full-year 2025.
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
The earnings call summary indicates positive developments such as improved gross margins due to supply chain diversification, effective cost management, and promising product launches. The Q&A reveals management's strategic focus on market expansion and addressing challenges, although some responses lack specificity. Overall, the company's initiatives and optimistic outlook, despite some uncertainties, suggest a positive sentiment. This, combined with the potential for margin improvements and market expansion, points to a likely positive stock price movement over the next two weeks.
The company reported significant revenue growth and improved gross margins, indicating strong financial performance. Despite increased operating expenses leading to a net loss, the guidance remains optimistic with continued investments in growth. The Q&A revealed some uncertainties about future guidance and FDA submissions, but the overall market strategy and expansion plans are positive. The stock price is likely to react positively over the next two weeks, especially given the record revenue growth and optimistic outlook for 2025.
The earnings report shows strong revenue growth and improved gross margins, suggesting positive financial performance. Despite increased operating expenses and net losses, the company maintains a solid cash position post-IPO. The Q&A indicates strategic investments in sales infrastructure and R&D, with a focus on future growth. While there are concerns about supply chain tariffs and unclear FDA submission details, the overall sentiment is optimistic, with expectations of accelerated growth post-2025. Given these factors, the stock is likely to experience a positive movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
